Single User
£3188
PDF
60 pages

Behcet’s Disease Forecast in 12 Major Markets 2016-2026


Behçet's disease (BD), also known as Silk Road Disease or Adamantiades-Behçet’s Disease, is a rare disease classified amongst a group of disorders termed “vasculitides”. The pathophysiology is thought to be autoimmune, linked to the HLA-B5/51 antigen. As a multisystem disease, clinical manifestations can involve nearly all systems of the body. The manifestations are self-limiting but recurrent and thus the majority of BD is characterized by a relapsing-remitting pattern.

This report provides the current prevalent population for Behcet’s disease across 12 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, Sweden, Turkey, China, Saudi Arabia and Egypt) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Behcet’s disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Behcet’s disease include:

  • Skin involvement with or without Erythema Nodosum
  • Genital ulcers
  • Eye involvement with or without Uveitis
  • Arthritis
  • CNS involvement
  • Vascular involvement

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Behcet’s disease’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Behcet’s disease and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Behcet’s disease’s prevalent population.
  • Identify sub-populations within Behcet’s disease which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Behcet’s disease patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions /Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Behcet’s Disease
  • Antigens and Pathergy in Bechet’s Disease Patients
  • Clinical Features of Bechet’s Disease Patients
    • Skin Manifestations
    • Ocular Manifestations
    • Joint Manifestations
    • CNS Manifestations
    • Vascular Manifestations
    • Cardiac Manifestations
    • Gastrointestinal Manifestations
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • International Study Group guidelines for diagnosis
  • The ICBD criteria
  • Prevalence of Behçet’s Disease, total
  • Prevalence of Behçet’s Disease, males
  • Prevalence of Behçet’s Disease, females
  • BD patients that are HLA-B5/51 positive, total patients
  • BD patients with positive Pathergy test, total patients
  • BD patients with erythema nodosum, total patients
  • BD patients with folliculitis, total patients
  • BD patients with papulopustular lesions, total patients
  • BD patients with genital ulcers, total patients
  • BD patients with uveitis, total patients
  • BD patients with hypopyon iritis, total patients
  • BD patients with retinitis, total patients
  • BD patients with visual loss and blindness, total patients
  • BD patients with arthritis, total patients
  • Neurological involvement in BD, total patients
  • Course of the neurological involvement in BD, total patients
  • Acute neurological with single episode, total patients
  • Acute neurological with relapsing-remitting pattern, total patients
  • Chronic neurological, primary progressive, total patients
  • Chronic neurological, progressive with further relapses, total patients
  • Cerebral haemorrhage in BD patients with neurological involvement, total patients
  • Vascular involvement in BD, total patients
  • DVT in BD, total patients
  • Superficial thrombophlebitis in BD, total patients
  • Cardiac involvement in BD, total patients
  • Gastrointestinal (GI) involvement in BD, total patients
  • Bowel perforation in BD patients with GI involvement, total patients
  • Abbreviations and acronyms used in the report
  • USA Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • USA Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • France Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • France Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Germany Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Germany Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Italy Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Italy Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Spain Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Spain Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Sweden Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Sweden Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Turkey Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Turkey Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Japan Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Japan Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • China Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • China Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Saudi Arabia Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Saudi Arabia Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
  • Egypt Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
  • Egypt Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
China, Egypt, France, Germany, Italy, Japan, Saudi Arabia, Spain, Sweden, Turkey, United Kingdom, United States of America